Key result
Long-acting metoprolol linked to antihypertensive and cerebroprotective effects in stage I-II hypertension.
Why the study?
The study addresses the antihypertensive and cerebroprotective effects of long acting metoprolol (Egiloc retard) in hypertensive patients with chronic hypertensive encephalopathy.
Does long acting metoprolol reduce blood pressure and improve cerebroprotective parameters in patients with stage I-II hypertension?
Does long acting metoprolol reduce blood pressure and improve cerebroprotective parameters in patients with stage I-II hypertension?
Answers are grounded in this paper and cite their sources.
Long-acting metoprolol effectively lowers blood pressure and may offer cerebroprotective benefits in patients with stage I-II hypertension.
Aim. The study addresses antihypertensive and cerebroprotective effects of long acting metoprolol (Egiloc retard, Egis, Hungary). Materials and methods. 47 objects with I-II stages of hypertension without serious concomitant diseases (25 males and 22 females, average age 51,7 ± 10,6 years) were included. Long acting metoprolol was administered (Egiloc retard, Egis, Hungary) in a dose of 25-100 mg given 1-2 times per day. 24-hour ambulatory blood pressure monitoring (ABPM), magnetic resonance tomography and dynamic contrast-enhanced perfusion computer scan of the brain with brain blood flow estimation were performed in all patients initially and after 6-month-therapy. Results. Egiloc retard showed a significant antihypertensive effect according to office and ABPM blood pressure. Egiloc retard normalizes 24-hour blood pressure profile in over-dippers and night-peakers. Subjective amelioration and improvement of functional and structural changes were found in hypertensive patients after 6-month therapy by Egiloc retard. Good tolerance and no significant abnormal changes of glucose and lipid metabolism were observed in patients taking Egiloc retard. It is also shown that Egiloc retard has the cerebroprotective effects.
No takes yet. Share an insight, caveat, or question.
Afanasieva et al. (2009) studied Hypertension with chronic hypertensive encephalopathy (n=47). Long acting metoprolol (Egiloc retard) was evaluated on Antihypertensive and cerebroprotective effects (office and ABPM blood pressure, brain blood flow). Long-acting metoprolol (Egiloc retard) administered for 6 months showed significant antihypertensive and cerebroprotective effects in patients with stage I-II hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: